Remdesivir data showing ‘meaningful benefits’: Biotech analyst
Piper Sandler senior biotech analyst Tyler Van Buren argues the FDA will be under a lot of pressure to approve remdesivir under an accelerated timeline based on the data.
//
via FOX BUSINESS NEWS https://ift.tt/2WbshXv
Коментари
Публикуване на коментар